Replimune To Present At ASCO Jun. 5-6
Replimune To Present At ASCO Jun. 5-6
WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.
馬薩諸塞州沃本，2022年5月26日(環球網)-臨牀階段生物技術公司Replimune Group，Inc.(納斯達克：REPL)今天宣佈，在2022年6月3日至6月7日在伊利諾伊州芝加哥舉行的2022年美國臨牀腫瘤學會年會上多次發表演講。
Details for the presentations are as follows:
介紹詳情如下：
Data presentation
數據展示
Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)
皮膚癌隊列的最新結果來自正在進行的RP1的1/2期多隊列研究，RP1是一種增強型溶瘤HSV，與nivolumab(IGNYTE)聯合使用
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 146
- Abstract: 9553
- 會議標題：黑色素瘤/皮膚癌
- 會議日期和時間：2022年6月6日星期一下午1：15-下午4：15
- 位置：麥考密克廣場，A展廳，海報146
- 摘要：9553
Trial in progress presentations
正在進行的試驗演示文稿
A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)
晚期皮膚鱗狀細胞癌(CERPASS)患者西米普利單抗±RP1的隨機對照開放標記2期研究
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 184a
- Abstract: TPS9593
- 會議標題：黑色素瘤/皮膚癌
- 會議日期和時間：2022年6月6日星期一下午1：15-下午4：15
- 位置：麥考密克廣場，A展廳，海報184a
- 摘要：TPS9593
An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
RP1是一項開放標記的多中心1b/2期研究，RP1是一種治療晚期皮膚惡性腫瘤(ARTACUS)實體器官移植受者的首屈一指的增強型溶瘤病毒
- Session Title: Melanoma/Skin Cancers
- Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 187a
- Abstract: TPS9597
- 會議標題：黑色素瘤/皮膚癌
- 會議日期和時間：2022年6月6日星期一下午1：15-下午4：15
- 位置：麥考密克廣場，A展廳，海報187A
- 摘要：TPS9597
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors
RP2是一種首屈一指的增強型溶瘤單純皰疹病毒，將抗CTLA-4抗體作為單一藥物並與尼伏單抗聯合治療晚期實體瘤患者
- Session Title: Developmental Therapeutics Immunotherapy
- Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 339b
- Abstract: TPS2704
- 會議標題：發育治療學免疫療法
- 會議日期和時間：2022年6月5日，星期日，上午8：00-上午11：00
- 位置：麥考密克廣場，展覽廳A，海報339b
- 摘要：TPS2704
An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors
RP3作為單一藥物與尼伏魯單抗聯合應用於實體瘤患者(PTS)的開放標記、多中心、1期研究
- Session Title: Developmental Therapeutics Immunotherapy
- Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
- Location: McCormick Place, Exhibit Hall A, Poster 340a
- Abstract: TPS2705
- 會議標題：發育治療學免疫療法
- 會議日期和時間：2022年6月5日，星期日，上午8：00-上午11：00
- 位置：麥考密克廣場，A展廳，海報340a
- 摘要：TPS2705
譯文內容由第三人軟體翻譯。